Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A1 | P18405 | 13/20 | 0.47 |
| ▸ | SRD5A2 | P31213 | 10/20 | 0.47 |
| ▸ | ATP1A1 | P05023 | 1/20 | 0.35 |
| ▸ | ATP1B1 | P05026 | 1/20 | 0.35 |
| ▸ | ATP1A3 | P13637 | 1/20 | 0.35 |
| ▸ | ATP1B2 | P14415 | 1/20 | 0.35 |
| ▸ | ATP1A2 | P50993 | 1/20 | 0.35 |
| ▸ | ATP1B3 | P54709 | 1/20 | 0.35 |
| ▸ | FXYD2 | P54710 | 1/20 | 0.35 |
| ▸ | ATP1A4 | Q13733 | 1/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL916849 | 0.86 | SRD5A1 (0.49) | SRD5A1SRD5A2 | |
| SCHEMBL917087 | 0.86 | SRD5A1 (0.52) | SRD5A1SRD5A2 | |
| SCHEMBL917802 | 0.84 | SRD5A1 (0.49) | SRD5A1SRD5A2 | |
| SCHEMBL917432 | 0.84 | SRD5A1 (0.50) | SRD5A1SRD5A2 | |
| SCHEMBL7909922 | 0.83 | SRD5A1 (0.44) | SRD5A1SRD5A2 | |
| SCHEMBL917162 | 0.83 | SRD5A1 (0.52) | SRD5A1SRD5A2 | |
| SCHEMBL917922 | 0.83 | SRD5A1 (0.49) | SRD5A1SRD5A2 | |
| SCHEMBL915714 | 0.82 | SRD5A1 (0.59) | SRD5A1SRD5A2 | |
| SCHEMBL917822 | 0.81 | SRD5A1 (0.44) | SRD5A1SRD5A2 | |
| SCHEMBL916418 | 0.81 | SRD5A1 (0.47) | SRD5A1SRD5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2371367-A1 | Method of treating men with testosterone supplement and 5alpha reductase inhibitor | MERCK SHARP & DOHME (I.A.) CORP. (US) | 2011-10-05 | — | — | EP | claimed |
| US-20110136769-A1 | METHOD OF TREATING MEN WITH TESTOSTERONE SUPPLEMENT AND 5ALPHA-REDUCTASE INHIBITOR | MERCK SHARP & DOHME CORP. (US) | 2011-06-09 | — | — | US | claimed |
| US-20110092470-A1 | METHOD OF TREATING MEN WITH ERECTILE DYSFUNCTION | MEEHAN ALAN | 2011-04-21 | — | — | US | claimed |
| EP-2305352-A1 | 5-alpha-reductase inhibitors for use in the treatment of men with metabolic and anthropometric disorders | Merck Sharp & Dohme Corp. (US) | 2011-04-06 | — | — | EP | claimed |
| US-20110015164-A1 | METHOD OF TREATING MEN WITH METABOLIC AND ANTHROPOMETRIC DISORDERS | MEEHAN ALAN | 2011-01-20 | — | — | US | claimed |
| EP-1865955-A4 | METHOD OF TREATING MEN WITH TESTOSTERONE SUPPLEMENT AND 5ALPHA-REDUCTASE INHIBITOR | MERCK & CO INC (US) | 2009-04-15 | — | — | EP | claimed |
| US-20080125403-A1 | Method of Treating Men with Metabolic and Anthropometric Disorders | MERCK & CO., INC. (US) | 2008-05-29 | — | — | US | claimed |
| EP-1865955-A2 | METHOD OF TREATING MEN WITH TESTOSTERONE SUPPLEMENT AND 5ALPHA-REDUCTASE INHIBITOR | Merck & Co., Inc. (US) | 2007-12-19 | — | — | EP | claimed |
| WO-2006104762-A2 | METHOD OF TREATING MEN WITH TESTOSTERONE SUPPLEMENT AND 5ALPHA-REDUCTASE INHIBITOR | MERCK & CO., INC. (US) | 2006-10-05 | — | — | WO | claimed |
| US-6352997-B1 | OXOAZASTEROIDS FOR TREATMENT OF FERTILITY PROBLEMS AND UROGENITAL DISORDERS | MERCK & CO., INC. | 2002-03-05 | — | — | US | claimed |
| US-6204273-B1 | TREATMENT OF ANDROGENIC SENSITIVE DISORDERS SUCH AS ACNE VULGARIS, SEBORRHEA, FEMALE HIRSUTISM, MALE PATTERN BALDNESS, AND BENIGN PROSTATIC HYPERPLASIA. | MERCK & CO., INC. | 2001-03-20 | — | — | US | claimed |
| EP-1009740-A1 | METHODS AND COMPOSITIONS FOR TREATING POLYCYSTIC OVARY SYNDROME | Merck & Co., Inc. (US) | 2000-06-21 | — | — | EP | claimed |
| US-5945412-A | ADMINISTERING ANDROSTENE DERIVATIVE 5-ALPHA REDUCTASE INHIBITOR | MERCK & CO., INC. (US) | 1999-08-31 | — | — | US | claimed |
| US-5935968-A | ADMINISTERING ANDROSTENE DERIVATIVE 5-ALPHA REDUCTASE INHIBITOR | MERCK & CO., INC. (US) | 1999-08-10 | — | — | US | claimed |
| EP-0724592-B1 | 16-SUBSTITUTED-4-AZA-ANDROSTANE 5-ALPHA-REDUCTASE ISOZYME 1 INHIBITORS | MERCK & CO INC (US) | 1999-01-07 | — | — | EP | claimed |
| WO-1998041509-A1 | METHODS AND COMPOSITIONS FOR TREATING POLYCYSTIC OVARY SYNDROME | MERCK & CO., INC. (US) | 1998-09-24 | — | — | WO | claimed |
| WO-1998025463-A1 | METHODS AND COMPOSITIONS FOR PREVENTING AND TREATING BONE LOSS | MERCK & CO., INC. (US) | 1998-06-18 | — | — | WO | claimed |
| EP-2371367-A1 | Method of treating men with testosterone supplement and 5alpha reductase inhibitor | MERCK SHARP & DOHME (I.A.) CORP. (US) | 2011-10-05 | — | — | EP | disclosed |
| US-5719158-A | 16-substituted-4-aza-androstane 5-alpha-reductase isozyme 1 inhibitors | MERCK & CO., INC. (US) | 1998-02-17 | — | — | US | disclosed |
| US-5543417-A | 5 Alpha-reductase inhibitor and at least one of an antibacterial agent, a keratolytic agent or an anti-inflammatory agent | MERCK & CO., INC. (US) | 1996-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110136769-A1 | METHOD OF TREATING MEN WITH TESTOSTERONE SUPPLEMENT AND 5ALPHA-REDUCTASE INHIBITOR | ADRA1D, ADRB1, AGER | SRD5A1 17/4885SRD5A2 26/4885ATP1A1 3688/4885 |
| US-20110015164-A1 | METHOD OF TREATING MEN WITH METABOLIC AND ANTHROPOMETRIC DISORDERS | CYP17A1, SHBG, CYP21A2 | SRD5A1 10/4885SRD5A2 4/4885ATP1A1 1240/4885 |
| US-20110092470-A1 | METHOD OF TREATING MEN WITH ERECTILE DYSFUNCTION | ADRA1D, ADRB1, AGER | SRD5A1 37/4885SRD5A2 53/4885ATP1A1 3130/4885 |
| US-20080125403-A1 | Method of Treating Men with Metabolic and Anthropometric Disorders | CYP17A1, SHBG, CYP21A2 | SRD5A1 10/4885SRD5A2 4/4885ATP1A1 1240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.